DK1585546T3 - KIM- 1- Antagonister og Brug til at Modulere Immunsystem - Google Patents

KIM- 1- Antagonister og Brug til at Modulere Immunsystem

Info

Publication number
DK1585546T3
DK1585546T3 DK03800194T DK03800194T DK1585546T3 DK 1585546 T3 DK1585546 T3 DK 1585546T3 DK 03800194 T DK03800194 T DK 03800194T DK 03800194 T DK03800194 T DK 03800194T DK 1585546 T3 DK1585546 T3 DK 1585546T3
Authority
DK
Denmark
Prior art keywords
kim
antagonists
cell
immune system
modulate immune
Prior art date
Application number
DK03800194T
Other languages
English (en)
Inventor
Paul D Rennert
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Application granted granted Critical
Publication of DK1585546T3 publication Critical patent/DK1585546T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
DK03800194T 2002-12-30 2003-12-29 KIM- 1- Antagonister og Brug til at Modulere Immunsystem DK1585546T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43693402P 2002-12-30 2002-12-30
PCT/US2003/041294 WO2004060041A2 (en) 2002-12-30 2003-12-29 Kim-1 antagonists and use to modulate immune system

Publications (1)

Publication Number Publication Date
DK1585546T3 true DK1585546T3 (da) 2008-12-08

Family

ID=32713106

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03800194T DK1585546T3 (da) 2002-12-30 2003-12-29 KIM- 1- Antagonister og Brug til at Modulere Immunsystem

Country Status (15)

Country Link
US (2) US7597887B2 (da)
EP (2) EP1585546B1 (da)
JP (2) JP4689275B2 (da)
CN (1) CN1835769B (da)
AT (1) ATE403440T1 (da)
AU (1) AU2003299925B2 (da)
CA (1) CA2512138C (da)
CY (1) CY1108480T1 (da)
DE (1) DE60322744D1 (da)
DK (1) DK1585546T3 (da)
ES (1) ES2311122T3 (da)
NZ (1) NZ541404A (da)
PT (1) PT1585546E (da)
SI (1) SI1585546T1 (da)
WO (1) WO2004060041A2 (da)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4602482B2 (ja) * 1996-05-24 2010-12-22 バイオジェン・アイデック・エムエイ・インコーポレイテッド 組織再生のモジュレーター
CA2512138C (en) * 2002-12-30 2013-07-16 Biogen Idec Ma Inc. Kim-1 antagonists and use to modulate immune system
JP2008500013A (ja) 2003-10-03 2008-01-10 ザ ブライハム アンド ウイメンズ ホスピタル，インコーポレイテッド Ｔｉｍ−３ポリペプチド
US20050197292A1 (en) * 2004-01-30 2005-09-08 Glennda Smithson Compositions and methods for treating T-cell mediated pathological conditions
TW200539890A (en) 2004-03-12 2005-12-16 Brigham & Womens Hospital Methods of modulating immune responses by modulating tim-1, tim-2 and tim-4 function
EP1865985B1 (en) * 2005-03-02 2010-08-25 Biogen Idec MA Inc. Kim-1 antibodies for treatment of th2-mediated conditions
WO2007058129A1 (ja) * 2005-11-18 2007-05-24 Nitto Boseki Co., Ltd. 抗原の測定法およびそれに用いるキット
ITFI20090005A1 (it) * 2009-01-19 2010-07-20 Alberto Chiarugi Formulazioni farmaceutiche per indurre immunosoppressione attraverso l'inibizione del fenomeno dell'epitope spreading e loro uso.
US20170101471A1 (en) * 2015-10-08 2017-04-13 The Board Of Trustees Of The Leland Stanford Junior University Blockade of tim-1 for treating graft-versus-host disease
WO2020186149A1 (en) * 2019-03-13 2020-09-17 The Brigham And Women's Hospital, Inc. Targeting regulatory b cells and their regulators for cancer immunotherapy
US11197910B1 (en) * 2020-08-19 2021-12-14 Vitruviae LLC Fusion proteins for the diagnosis, prophylaxis and treatment of infectious diseases

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
GB2183662B (en) 1985-04-01 1989-01-25 Celltech Ltd Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
EP0401384B1 (en) 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
EP0503648B1 (en) 1991-03-12 2000-06-07 Biogen, Inc. CD2-Binding domain of lymphocyte function associated antigen 3
US5622861A (en) 1994-08-05 1997-04-22 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA encoding hepatitis A virus receptor
US5541087A (en) 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
US6066322A (en) * 1995-03-03 2000-05-23 Millennium Pharmaceuticals, Inc. Methods for the treatment of immune disorders
US6165733A (en) 1996-05-23 2000-12-26 Chiron Corporation γ II adaptin
JP4602482B2 (ja) * 1996-05-24 2010-12-22 バイオジェン・アイデック・エムエイ・インコーポレイテッド 組織再生のモジュレーター
JP2001503271A (ja) 1996-11-01 2001-03-13 ヒューマン ジノーム サイエンシーズ，インコーポレイテッド ヒト粘膜アドレシン細胞接着分子―１（ＭＡｄＣＡＭ―１）およびそのスプライス変異体
JP4094066B2 (ja) * 1996-12-06 2008-06-04 バーテックス ファーマシューティカルズ インコーポレイテッド インターロイキン−１β変換酵素のインヒビター
KR100764256B1 (ko) * 1998-01-23 2007-10-05 에프. 호프만-라 로슈 아게 인간 인터루킨-12에 대한 항체
EP1051426A4 (en) 1998-01-30 2003-04-09 Human Genome Sciences Inc 67 HUMAN SECRETED PROTEINS
CN1160075C (zh) 1998-03-11 2004-08-04 卫福有限公司 杂环酰胺化合物在制备IgE抗体产生抑制剂中的用途
US6228642B1 (en) * 1998-10-05 2001-05-08 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of tumor necrosis factor-(α) (TNF-α) expression
AU5309600A (en) 1999-06-02 2000-12-18 Millennium Pharmaceuticals, Inc. Compositions and methods for the treatment and diagnosis of immune disorders
JP2004500879A (ja) * 2000-06-16 2004-01-15 バイオジェン　インコーポレイテッド 腎の調節エレメントおよびそれらの使用方法
DK1401869T3 (da) * 2001-06-01 2008-04-28 Biogen Idec Inc Molekyler og fremgangsmåder til inhibering af udskillkelse af kim 1
JP4572276B2 (ja) * 2001-06-29 2010-11-04 ザ ボード オブ トラスティーズ オブ ザ リランド スタンフォード ジュニア ユニヴァーシティ Ｔ細胞調節遺伝子およびその使用方法
US7838220B2 (en) * 2001-06-29 2010-11-23 The Board Of Trustees Of The Leland Stanford Junior University T cell regulatory genes associated with immune disease
CA2459219A1 (en) 2001-09-17 2003-03-27 Protein Design Labs, Inc. Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer
WO2003042661A2 (en) 2001-11-13 2003-05-22 Protein Design Labs, Inc. Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
US7687454B2 (en) * 2001-12-03 2010-03-30 The University Of British Columbia Effectors of innate immunity determination
JP4694128B2 (ja) * 2002-01-30 2011-06-08 ザ ブライハム アンド ウイメンズ ホスピタル， インコーポレイテッド ＴＩＭ−３、Ｔｈ１特異的細胞表面分子に関連した組成物および方法
AU2003228336B2 (en) * 2002-03-19 2009-07-30 Curagen Corporation Therapeutic polypeptides, nucleic acids encoding same, and methods of use
GB0215509D0 (en) 2002-07-04 2002-08-14 Novartis Ag Marker genes
CA2512138C (en) * 2002-12-30 2013-07-16 Biogen Idec Ma Inc. Kim-1 antagonists and use to modulate immune system
CA2519528C (en) 2003-03-19 2016-01-26 Abgenix, Inc. Antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen and uses thereof
US20050119210A1 (en) 2003-05-20 2005-06-02 Xiaobing Be Compositions and methods for diagnosing and treating cancers
TW200539890A (en) * 2004-03-12 2005-12-16 Brigham & Womens Hospital Methods of modulating immune responses by modulating tim-1, tim-2 and tim-4 function
BRPI0509139A (pt) * 2004-03-24 2007-08-28 Telos Fharmaceuticals Inc composição, e, método de estimulação de uma resposta imune em um indivìduo, de tratamento profilático de uma doença, de melhoramento de um sinal ou sintoma associado com uma doença, de alvejamento de um tumor, de inibição do crescimento de tumor, e de detecção de um tumor

Also Published As

Publication number Publication date
EP1585546A2 (en) 2005-10-19
EP1585546A4 (en) 2006-05-10
SI1585546T1 (sl) 2008-12-31
JP2010280728A (ja) 2010-12-16
US20060222648A1 (en) 2006-10-05
ES2311122T3 (es) 2009-02-01
ATE403440T1 (de) 2008-08-15
PT1585546E (pt) 2008-11-14
US20100080798A1 (en) 2010-04-01
NZ541404A (en) 2007-05-31
CY1108480T1 (el) 2014-04-09
CA2512138C (en) 2013-07-16
JP5368400B2 (ja) 2013-12-18
WO2004060041A3 (en) 2005-01-27
AU2003299925B2 (en) 2011-10-27
WO2004060041A2 (en) 2004-07-22
EP1585546B1 (en) 2008-08-06
HK1084326A1 (en) 2006-07-28
CN1835769B (zh) 2011-06-29
AU2003299925A1 (en) 2004-07-29
AU2003299925A2 (en) 2004-07-29
JP2006512397A (ja) 2006-04-13
CA2512138A1 (en) 2004-07-22
EP2025345A1 (en) 2009-02-18
DE60322744D1 (de) 2008-09-18
US7597887B2 (en) 2009-10-06
CN1835769A (zh) 2006-09-20
JP4689275B2 (ja) 2011-05-25

Similar Documents

Publication Publication Date Title
CY1108480T1 (el) Ανταγωνιστες κιμ-1 και χρηση για την τροποποιηση του ανοσιακου συστηματος
UA85597C2 (ru) Четвертичные соли как антагонисты ccr2
EP1576011A4 (en) INHIBITION OF IL-17 PRODUCTION
ES2319886T3 (es) Compuestos azabiciclicos condensados que inhiben el sutipo 1 del receptor valinoide (vr1).
DK1616184T3 (da) Fremgangsmåde og kit til at påvise tidlig begyndelse af renal tubulær cellebeskadigelse
EP1809280A4 (en) MITOTIC KINESINE INHIBITORS AND METHOD OF USE THEREOF
DK1583541T3 (da) Forbindelser og fremgangsmåder til at øge neurogenese
BRPI0411825A (pt) inibidores de p38 quinase a base de heterociclo de 5 elementos
LU92218I2 (fr) Mirabegron ou un de ses sels
EP1953851A4 (en) ELECTRODE FOR A SECONDARY BATTERY AND SECONDARY BATTERY THEREWITH
NO20055253L (no) Behandling av autoimmun sykdom i en pasient med utilstrekkelig respons pa en TNF-alfa-inhibitor
TNSN04001A1 (fr) Association d'un antagoniste des recepteurs d'aldosterone et d'un inhibiteur de hmg-coa- reductase.
DE69937994D1 (de) Prophylaktische oder therapeutische mittel gegen entzündliche erkrankungen des verdauungstraktes enthaltend antagonistische il-6 rezeptor antikörper
ES2193589T3 (es) Aldehido del acido n-(2-(5-benciloxicarbonil-amino-6-oxo-2-(4-fluorofenil)-1,6-dihidro-1-pirimidinil)acetoxil)-l-aspartico como un inhibidor (in vivo) del enzima de conversion de la interleucina-1beta.
DE60144514D1 (de) Verwendung von il-18 inhibitoren
MXPA04006555A (es) Piridazinodionas-3,4-disustituidas como antagonistas de receptor de quimiocina cxc.
EA200401341A1 (ru) Применение остеопротегерина для лечения и/или профилактики фиброзного заболевания
EE9700090A (et) Interleukiin-1 retseptori antagonisti intratsellulaarne isovorm
WO2006038006A3 (en) 5-sulfonyl-1-piperidinyl substituted indole derivatives as 5-ht6 receptor antagonists for the treatment of cns disorders
AR028772A1 (es) 5-aminoalquil-pirazol[4,3-d] pirimidinas
MX2007000046A (es) Compuestos, composiciones y metodos de imidazolo relacionados para su uso.
TR200103448T2 (tr) IL-8 reseptör antagonistleri.
EP1564177A4 (en) LIFT FACILITY
ITMI20041954A1 (it) "procedimento per stimare lapendenza longitudinale del piano stradale"
DE602005014364D1 (de) Vla-4-antagonisten